3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Acrocephalosyndactylia
6
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Myeloproliferative Disorders
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Solid Tumor
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Temozolomide
32
Radiotherapy
11
Bevacizumab
10
Surgical Procedures, Operative
7
IL13-PE38
7
TIC10 compound
6
Lomustine
6
Carboplatin
6
Radiation
5
Chlorotoxin
5
vorasidenib
4
trametinib
4
dabrafenib
4
Valacyclovir
4
OKN 007
4
Flucytosine
4
Dianhydrogalactitol
4
Cyclophosphamide
4
vocimagene amiretrorepvec
3
abemaciclib
3
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
CLR1404
3
trans-sodium crocetinate
2
pembrolizumab
2
olutasidenib
2
marizomib
2
lenvatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioma
×
pemigatinib
×
Clear all
NCT05267106
2025-12-30
FIGHT-209
Incyte Corporation
Phase 2
Terminated
83 enrolled
18 charts